GSK 3039294

Drug Profile

GSK 3039294

Alternative Names: GSK-3039294

Latest Information Update: 08 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Neuroprotectants
  • Mechanism of Action Serum amyloid P component inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Amyloidosis

Most Recent Events

  • 22 Nov 2017 GSK suspends patient enrolment in a phase I trial for Amyloidosis in United Kingdom (PO) (NCT02603172)
  • 20 Nov 2015 Preclinical trials in Amyloidosis in United Kingdom (PO) before November 2015
  • 20 Nov 2015 GSK plans a phase I trial for Amyloidosis in United Kingdom (PO) (NCT02603172)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top